Elfandy H, Armenia J, Pederzoli F, et al. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res. 2019;17(2):446-456. doi:10.1158/1541-7786.MCR-18-0440.
Brooks AN, Choi PS, de Waal L, et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One. 2014;9(1):e87361. doi:10.1371/journal.pone.0087361.
Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169-175. doi:10.1038/nature20805.
Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378-384. doi:10.1038/nature21386.
Schumacher SE, Shim BY, Corso G, et al. Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. PLoS One. 2017;12(4):e0176045. doi:10.1371/journal.pone.0176045.
Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of persistence and antibiotic response in colorectal cancer. Science. 2017;358(6369):1443-1448. doi:10.1126/science.aal5240.
Yurgelun MB, Chittenden AB, Morales-Oyarvide V, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019;21(1):213-223. doi:10.1038/s41436-018-0009-5.
Qian ZR, Rubinson DA, Nowak JA, et al. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018;4(3):e173420. doi:10.1001/jamaoncol.2017.3420.
Pectasides E, Stachler MD, Derks S, et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018;8(1):37-48. doi:10.1158/2159-8290.CD-17-0395.
Khalaf N, Yuan C, Hamada T, et al. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology. 2018;154(5):1380-1390.e5. doi:10.1053/j.gastro.2017.12.001.